PMC

(A) A whole structure view and (B) a close-up view of IL-13 are shown via surface and cartoon representations. The tralokinumab and lebrikizumab structures were transformed after they bound with IL-13. The gradation colour of IL-13 was displayed using the spectrum function of PyMOL software, thus colouring the N-terminal to C-terminal domains, in order, as blue, cyan, green, yellow, orange, and red. Tralokinumab and lebrikizumab, including complementarity determining regions, were depicted as black. Residues at position 144 of IL-13 protein were indicated by arrows and shown in stick representation.

Effect of lebrikizumab treatment on the change in FEV₁ values in adults with asthma. For all patients at week 12 (A), the increase from baseline in mean (±SE) FEV₁ was higher in the lebrikizumab group (9.8% ± 1.9%) than in the placebo group (4.3% ± 1.5%) (P = 0.02). In the subgroup of patients with high serum periostin levels at week 12 (B), the increase from baseline in mean (±SE) FEV₁ was higher in the lebrikizumab group (14.0% ± 3.1%) than in the placebo group (5.8% ± 2.1%) (P = 0.03). In the subgroup of patients with low serum periostin levels at week 12 (C), the increase from baseline in mean (±SE) FEV₁ was similar in the lebrikizumab group (5.1% ± 2.4%) to the placebo group (3.5% ± 2.1%); (P = 0.61). From The New England Journal of Medicine, Corren J, Lemanske RF, Hanania NA, et al, Lebrikizumab treatment in adults with asthma. 12, 1088–1098. Copyright © 2011 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Abbreviation: FEV₁, forced expiratory volume in 1 second.

Trial design, with lebrikizumab 125 mg or placebo administered subcutaneously on day 1, day 8, week 4 and week 8 during the 12‐week placebo‐controlled period. SC, subcutaneous

Study design schematic. Lebri, lebrikizumab; R, masked randomisation. *After the last dose of study drug during the optional active‐treatment extension (or during the placebo‐controlled period for patients who opt not to participate in the active‐treatment extension), all patients were to be followed‐up for safety for 24 weeks. This includes the 4 weeks after the final dose during the placebo‐controlled period or the active‐treatment extension and a 20‐week safety follow‐up period